Navigation Links
Odyssey Thera Granted U.S. Patent for Animal Imaging
Date:12/12/2007

SAN RAMON, Calif., Dec. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation Assays (PCA) in whole animals: applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy." This is the twelfth patent issued for Odyssey Thera's PCA process.

The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at Odyssey Thera to monitor drug response. The invention makes it possible to monitor specific biochemical parameters, including the extent and kinetics of drug target modulation, in a live subject.

"This patent extends our broad estate in drug discovery technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "One of the most challenging aspects of drug discovery is transitioning drug candidates from the test tube, to native targets in living cells, and from there to live subjects. With this invention, drug discovery and development are achieved with a single system that faithfully monitors the activity of a drug at each step." Dr. Westwick continues, "Whole animal studies using fluorescence or luminescence detection are widely used in the pharmaceutical industry, but strategies were needed to increase the scope of biochemical activities that can be tracked. The approaches described here will significantly increase the value of live subject imaging efforts."

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for chronic diseases. Odyssey Thera is leveraging its proprietary pathway-based approach and human cell models to optimize drug development for its own programs and for its premier pharmaceutical company partners.

To learn more about Odyssey Thera visit http://www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... AUSTIN, Texas , Feb. 11, 2016  Vermillion, ... focused on gynecologic disease, today announced the formation of ... --> --> Pelvic ... in both diagnosis and management. Once pregnancy is ruled ... fallopian tubes and ovaries, advanced endometriosis, benign ovarian tumors ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/10/2016)... Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announce that Mitsui & Co. Ltd., its partner in ... plant, is investing an additional CDN$25 million in the ... stake from 30% to 40%.  Mitsui will also play ... produced in Sarnia , providing dedicated ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/11/2016)... Calif. , Jan. 11, 2016 Synaptics ... human interface solutions, today announced that its ClearPad ® ... integration (TDDI) products won two separate categories in the ... Mobile Innovator and Best Technology Breakthrough. The Synaptics ® ... cost, a simplified supply chain, thinner devices, brighter displays ...
Breaking Biology News(10 mins):